Close
Close

Question 1 of 3: What's your biggest struggle with IBD?

Next

Question 2 of 3: How prepared do you feel to take care of your health on your own?

Next

Question 3 of 3: Where do you turn to for emotional support?

Complete

Colorful graphic bar

For Parents

You recently learned that your child has Crohn’s disease or ulcerative colitis. Now you’re taking an important step: learning about these conditions, how they’re treated, and how your child can learn to live with IBD. 

The Crohn's & Colitis Foundation's purpose is to start you on an educational path—to inform you of some key points about Crohn’s disease and ulcerative colitis, and what you may expect. You won’t become an expert overnight, but gradually you’ll learn more. And the more you know, the better you’ll be able to become an advocate for your child. Most important: You’ll be an active member of your child’s healthcare team.

 

Podcast Series for IBD Patients and Families - Maintaining Healthy Nutrition in Pediatric IBD Patients

Recent News

Stay up-to-date with the most current news and information about the Crohn's & Colitis Foundation, as well as Crohn's disease and ulcerative colitis. Below you’ll find our most recent press releases, along with other articles written by the Crohn's & Colitis Foundation.

This media content highlights the public research outcomes related to our initiatives, studies, and clinical trials. In addition, you can read our expert commentary related to research articles culled from external media sources.

Survey for Clinical Trial Enrollment Patient Preferences

October 10, 2018

The Crohn’s & Colitis Foundation and RTI International are working together to conduct a survey of caregivers of pediatric patients with inflammatory bowel disease. The goal of this survey is to understand why some patients choose to participate in clinical trials and others do not. Understanding this will help researchers find ways to boost clinical trial enrollment and incorporate patient preferences in clinical trial design. This survey takes 20 minutes or less to complete. All answers will be kept private.

Leading Gastroenterology Organizations Announce Funding to Improve Vaccine Utilization and Preventive Health Maintenance in Patients with Inflammatory Bowel Diseases

March 8, 2019

The American College of Gastroenterology (ACG), the American Gastroenterological Association (AGA), and the Crohn’s & Colitis Foundation (Foundation), in partnership with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address vaccine utilization, promote health maintenance, and increase preventive care services in patients with inflammatory bowel diseases (IBD).

Increased patient-provider communication affects overall outcomes at every stage of the IBD patient journey

February 7, 2019

It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). Currently, there are no cures for these diseases. For many patients their disease impacts other areas of their health and well-being including aspects of their reproductive and mental health.

Improving diagnosis leads to better outcomes in patients with inflammatory bowel disease (IBD)

February 7, 2019

For many patients the path to diagnosis and effective treatment is long and arduous, leading to delayed treatment and increased complications. Studies being presented at the Crohn’s & Colitis Congress — a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, on February 7-9 – reinforces the need for and highlights advances towards improved diagnosis of patients with IBD.

Emerging therapies show benefit to patients with Crohn’s disease and ulcerative colitis

February 7, 2019

It is estimated that 3 million Americans live with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. Currently, there are no cures for these diseases. Studies being presented at the Crohn’s & Colitis Congress — a partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association, in Las Vegas, NV, on February 7-9 – highlights advancement in treatments for patients with IBD.

Crohn’s & Colitis Foundation Launches New Online Journal: Crohn’s & Colitis 360 to Inform and Catalyze Patient-Centered IBD Care

January 23, 2019

The Crohn’s & Colitis Foundation is launching a new open access journal to engage, inform, and catalyze dialogue on state-of-the-art, comprehensive care for more than 3 million Americans living with inflammatory bowel diseases (IBD). Crohn’s & Colitis 360 is a peer-reviewed, online-only forum for the publication of novel research and insights across key disciplines in IBD care. As an open access (OA) publication, Crohn’s & Colitis 360 is free and allows unrestricted online access to research outputs with no access fees. Manuscript submissions are now open at www.crohnscolitis360.org, with the first issue slated for May.

Organizers of the 2019 Crohn’s & Colitis Congress Announce Agenda & Call for Abstracts

August 21, 2018

The Crohn’s & Colitis Congress®, the premier meeting for clinical and research professionals in the IBD space, has opened registration for the 2019 meeting. A partnership of the Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA), the meeting will include four main sessions, as well as basic science sessions and pre-Congress workshops. The 2019 Crohn’s & Colitis Congress will take place February 7-9, 2019, at the Bellagio Hotel in Las Vegas.

Landmark Study to Compare the Effectiveness of Biologic or Small Molecule Therapies in Inflammatory Bowel Diseases (IBD) Receives Funding

May 17, 2018

Crohn’s disease (CD) and ulcerative colitis (UC), collectively referred to as inflammatory bowel diseases (IBD), which may affect as many as 3 million Americans, cost over $6 billion annually, and cause substantial patient morbidity, missed work and school, and diminished quality of life. Currently, anti-TNF therapy is considered first line treatment for moderate-to-severe IBD. However, up to 80 percent of patients do not respond or, ultimately, lose response to anti-TNF. New treatments provide additional options from which to choose, however, there are no head-to-head studies that compare these new treatments.

Powered by Blackbaud
nonprofit software